Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company's 4.5

Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company's 4.50% Convertible Senior Notes Due 2024

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference

Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference

Clovis (CLVS) reports mixed third-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially.

Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact

Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q3 2020 Results - Earnings Call Transcript

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2020, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for the rest of the year. “We are pleased that third quarter revenues for Rubraca grew slightly over the same period in 2019, despite a very challenging sales environment caused by COVID-19, which has severely limited oncology patient visits and cancer

Clovis Oncology Announces Third Quarter 2020 Operating Results

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes

Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets. Clovis' senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the company's results in greater detail. The conference call is being webcast and can be accessed from the Clovis Oncology website at www.clovisoncology.com. A replay of the webcast will be av

Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5

Despite an almost 60% rise since the March 23 lows of this year, at the current price of around $6 per share, we believe Clovis Oncology stock has more room for growth. CLVS stock has rallied from under $4 to $6 off the recent bottom, compared to a 45% move for S&P500.

Clovis Oncology Stock Down 18% This Week: Time To Buy?

BOULDER, Colo.--(BUSINESS WIRE)--New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline

New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting

Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020

Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology to Present at the H.C.

Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?

Clovis (CLVS) Down 17.3% Since Last Earnings Report: Can It Rebound?

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, mCRPC

FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)

BOULDER, Colo.--(BUSINESS WIRE)--JCO Publishes Additional Data from CLVS TRITON2 Clinical Trial Evaluating Rubraca® for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations

Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations

Clovis (CLVS) reports dismal second-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially.

Clovis (CLVS) Q2 Earnings Lag, Revenues Show Coronavirus Impact

Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q2 2020 Results - Earnings Call Transcript

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Announces Second Quarter 2020 Operating Results

Clovis Oncology Announces Second Quarter 2020 Operating Results

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in.

Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc.

Clovis Oncology to Announce Second Quarter 2020 Financial Results and Host Webcast Conference Call on August 6

Clovis (CLVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Clovis (CLVS) Upgraded to Buy: Here's Why

Clovis Oncology (CLVS) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

Is Clovis Oncology (CLVS) Stock a Solid Choice Right Now?

DUBLIN and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Clovis Oncology, Inc. (Nasdaq: CLVS) today announced positive preclinical data from a study designed to evaluate the combination potential of ALKS 4230, Alkermes' investigational engineered...

New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II

Clovis (CLVS) is developing Rubraca as monotherapy as well as in combination with Bristol-Myers' Opdivo as first-line maintenance treatment for ovarian cancer in the phase III ATHENA study.

News for Clovis Oncology Stock (CLVS)